Login
$ICCC
$11.64 +$0.22 (1.93%) Pre-market

$ICCC SEC Filings

Filed On Filing
16 Nov 2026 Form 4: te Boekhorst Paul Francis Olivier, Director

Received 16,393 shares by exercise or conversion ($100K)

13 Nov 2026 8-K: Results of Operations and Financial Condition
12 Nov 2026 FORM 10-Q
12 Nov 2026 FORM S-8
13 Oct 2026 8-K: Results of Operations and Financial Condition

ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results

13 Aug 2026 FORM 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today ann...

09 Jul 2026 8-K: Results of Operations and Financial Condition

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

22 Jun 2026 Form 4: te Boekhorst Paul Francis Olivier, Director

Bought 8,000 shares ($76K)

17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The 2026 Annual Meeting of Stockholders of the Company (the “2026 Annual Meeting”) was held by remote communication in the form of both a dial-in conference call and an audio webcast rather than an in-person event on Thursday, June 11, 2...

10 Jun 2026 8-K: Regulation FD Disclosure

In late December 2025 and early January 2026, ImmuCell Corporation (“ImmuCell” or the “Company”) announced the suspension of plans to manufacture its Re-Tain® product in-house, and instead convert most of the related facilities and equip...

14 May 2026 8-K: Results of Operations and Financial Condition

PORTLAND, Maine – May 14, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudi...

14 May 2026 FORM 10-Q
13 May 2026 FORM 10-K/A
08 May 2026 8-K: Entry into a Material Definitive Agreement

On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying...

24 Apr 2026 Proxy statement: annual meeting on June 11, 2026

CEO pay $676K · say-on-pay vote

23 Apr 2026 Form 3: DiMarco Anthony, Director
23 Apr 2026 Form 3: Guillemette Gilles, Director
16 Apr 2026 Form 4: Turner Kathy V, Director

Granted 17,899 Non Qualified Stock Options (Right to buy)

16 Apr 2026 Form 4: Tomsche David Scott, Director

Granted 11,933 Non Qualified Stock Options (Right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support